VisionPoint Advisory Group LLC Buys New Position in Charles River Laboratories International, Inc. (NYSE:CRL)

VisionPoint Advisory Group LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, HoldingsChannel reports. The firm acquired 9,589 shares of the medical research company’s stock, valued at approximately $1,751,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. Creative Planning raised its stake in Charles River Laboratories International by 4.0% during the 3rd quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock valued at $920,000 after acquiring an additional 180 shares during the last quarter. Blue Trust Inc. raised its stake in Charles River Laboratories International by 28.6% during the 3rd quarter. Blue Trust Inc. now owns 1,877 shares of the medical research company’s stock valued at $388,000 after acquiring an additional 418 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at approximately $83,800,000. Riverwater Partners LLC raised its stake in Charles River Laboratories International by 2.3% during the 3rd quarter. Riverwater Partners LLC now owns 5,643 shares of the medical research company’s stock valued at $1,089,000 after acquiring an additional 126 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Charles River Laboratories International by 152.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 49,030 shares of the medical research company’s stock valued at $9,657,000 after acquiring an additional 29,621 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the subject of several analyst reports. Barclays reduced their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research note on Monday, November 18th. JPMorgan Chase & Co. cut their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday. Robert W. Baird cut their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, UBS Group reissued a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $162.63 on Friday. The business has a 50 day moving average price of $173.39 and a 200 day moving average price of $188.81. The company has a market capitalization of $8.32 billion, a P/E ratio of 1,084.19, a PEG ratio of 6.77 and a beta of 1.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.46 EPS. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.41 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).